Eric Rogers is a registered U.S. patent attorney who prosecutes domestic and international patents, assists clients in strategic patent portfolio development, provides licensing and freedom-to-operate advice as well as guidance in USPTO actions and claims. His technical concentrations are in biotechnology, biopharma, biochemistry, immunology, genetics, and molecular biology.

Eric's experience includes:

• Patent drafting, patent prosecution, patentability in biotech: antibodies, ADC, engineered cells, CAR-T;


• Preparing and prosecuting U.S./foreign patent applications in biotech and biopharma focused on immunotoxins, immunotherapy, antibodies, oncoimmunology; and


• Working in-house at biotech startup focused on cancer.

Eric has authored several law review articles and co-authored several scientific research articles.

RESEARCH EXPERIENCE

Eric's Ph.D. thesis research was directed to Aurora and polo kinases. Throughout his academic pursuits, he conducted research in various areas:

• Research Associate, UT Southwestern, Dept. of Pharmacology/Green Center for Systems Biology, Ranganathan Lab, protein biophysics, 2008, 2009;


• Post-Doctoral Fellow, UCSD, Dept. of Chemistry and Biochemistry, Donoghue Lab, FGFR3 signaling and tamoxifen resistance, 2005, 2006;


• Doctoral Student, UT Southwestern, Dept. of Molecular Biology, Lin Lab, studied embryonic development, cell fate and cell division, 1999-2004; and


• Research Assistant, UTHSCSA, Dept. of Biochemistry, Serwer Lab, developed biochemical methods to separate biological macromolecules, 1998, 1999.

SELECT PATENT APPLICATIONS DRAFTED AND PROSECUTED

Antigen-Seeding with Immunotoxins for Immuno-oncology:

• PCT/US2016/043902 - published as WO2017019623 on 2/02/17
  
  US national stage: 15/421758 - published as US20180243432 on 8/30/18

Immunotoxins:

• PCT/US2020/051589 - published as WO2021055816 on 3/25/21
  
  US 17/025729 and US 17/027120 - published as US20210079097 and US20210079098 on 3/18/21


• PCT/US2020/014831 - published as WO2020154531 on 7/30/20
  
  US national stage: 16/751144 - published as US20200231650 on 7/23/20


• PCT/US2019/027627 - published as WO2019204272 on 10/24/19
  
  US national stage: 17/0725632 - published as US20210040160 on 2/11/21


• PCT/US2014/023198 - published as WO2014164680 on 10/09/14
  
  US 1045035

Immunotoxin Improvements:

• PCT/US2016/016580 - published as WO2016126950 on 8/11/16
  
  US 10392425


• PCT/US2015/035179 - published as WO2015191764 on 12/17/15
  
  US 10815469

Antibodies for Immuno-oncology:

• PCT/US2019/056203 - published as WO2020081493 on 4/23/20

De-Immunization:

• PCT/US2015/012970 - published as WO2015113007 on 7/30/15
  
  US national stage: 15/114487 - published as US20160340394 on 11/24/16